SCIENCE TALES

AI is everywhere—it brings hopes of accelerating industrial processes and making our lives easier and our work more efficient. It also brings fears of unexplainable black box calculations, of unintended consequences, and human job loss.

In the pharmaceutical industry, AI opens up the possibility of developing medications more quickly and tailoring them more precisely to the needs of individual patients.

But to truly revolutionize the multibillion-dollar process of drug development using AI, it requires the right strategies, technological foundations, and, above all, high-quality data.

In this keynote, I explore the potential of AI beyond the hype and draft scenarios of how AI-driven drug development could look like.

How will the medicine of the future look? Healthcare and medicine are on the verge of transformative change, driven by new technologies such as artificial intelligence, telemedicine, and wearable devices.
Alongside the technologization and virtualization of medicine, there is a shift from reactive "fix the broken" approaches to preventative strategies and from one-size-fits-all treatments to personalized medicine.

In this future, human healthcare professionals and machines will work hand-in-hand to deliver the best possible care, with empowered patients acting as equal decision-makers who understand and access their own healthcare data. However, a darker scenario could see medicine becoming fully industrialized and dehumanized.

In this keynote, I outline the key trends shaping the future of medicine and discuss the opportunities and risks that accompany these developments.

What if aging wasn’t inevitable? In this thought-provoking keynote, I explore how cutting-edge biotechnology, genetic research, and AI are reshaping our understanding of aging—not as a natural decline, but as a process that can be slowed, altered, or even reversed.

From the work of pioneering companies like Altos Labs to the ethical and societal questions raised by radically extended lifespans, this keynote blends deep scientific insight with a broader cultural lens. It is designed to challenge assumptions, inspire new perspectives, and equip your audience with a clear understanding of where longevity science is headed—and what it means for us all.

By the end of the keynote, the audience won’t just be asking “Can we live longer?”—they’ll be asking “How will we live differently if we do?”

Artificial intelligence feels omnipresent—especially since large language models like ChatGPT have entered our personal devices and workflows. In healthcare, pharma, biotech, and MedTech, AI has sparked extraordinary hopes: faster drug discovery, smarter diagnostics, and more personalized medicine.

Yet ten years into the so-called AI revolution, with billions invested and over 100 AI-discovered molecules in clinical trials, the results remain mixed. Industry leaders face a challenging paradox: enormous potential on one hand, and persistent uncertainty on the other.

In this keynote, we take a grounded look at the true state of AI in biotech and pharma. We’ll unpack:

• What’s working, what’s still aspirational

• The technological, regulatory, and cultural frictions slowing adoption

• Why strategic entry—even on a small scale—is essential to build internal AI literacy and resilience

By the end of the keynote, the audience will gain a clear-eyed perspective on how to cut through the hype and move toward thoughtful, strategic adoption—positioning AI not as a buzzword, but as a catalyst for real innovation.